KUALA LUMPUR (Jan 14): Based on corporate announcements and news flow today, stocks that may be in focus tomorrow (Jan 15) include: FGV Holdings Bhd, TA Enterprise Bhd, AirAsia X Bhd (AAX), Pharmaniaga Bhd, Boustead Heavy Industries Corp Bhd (BHIC), See Hup Consolidated Bhd, Tek Seng Holdings Bhd, JCY International Bhd, George Kent (Malaysia) Bhd, Dayang Enterprise Holdings Bhd, Red Ideas Holdings Bhd, Jiankun International Bhd and Perak Transit Bhd.
The Federal Land Development Authority (Felda) bought 22 million shares in
FGV Holdings Bhd in the open market yesterday for RM28.38 million as part of its efforts to take the plantation company private. The shares were bought at RM1.29 per share, slightly lower than the RM1.30 cash offer Felda made for FGV shares.
are among the stocks to watch on Wednesday, according to JF Apex Research.
Pharmaniaga is partnering with China s Sinovac Life Sciences Co Ltd for the supply of 14 million doses of Covid-19 vaccine in Malaysia.
Pharmaniaga expects the vaccine to be distributed to the public by the end of March, according to managing director Datuk Zulkarnain Md Eusope.
Under the deal, Pharmaniaga will carry out the fill and finish process of the vaccine developed by Sinovac.
MTD ACPI Engineering has won a RM33.44mil construction contract from the Public Works Department in Pahang.
Mulpha International s wholly-owned unit Mulpha Australia (Holdings) Pty Ltd has accepted a syndicated credit facility of A$342mil (RM1.07bil) from Oversea-Chinese Banking Corp Ltd and United Overseas Bank Ltd in Australia to finance the refurbishment works at InterContinental Sydney Hotel and to refinance its existing borrowings.
The vaccine would be the first to be manufactured in Malaysia at the small volume injectable high-tech plant owned by Pharmaniaga’s wholly-owned subsidiary, Pharmaniaga LifeSciences Sdn Bhd, in Puchong, Selangor, Pharma Niaga MD Zulkarnain Md Eusope told reporters after the signing of an agreement between pharmaniaga and Sinovac Life Sciences Co Ltd yesterday.
KUALA LUMPUR: Phamaniaga Bhd has the capacity to manufacture two million doses of Covid-19 vaccine developed by China’s Sinovac Life Sciences Co Ltd per month beginning March this year.
Group managing director Datuk Zulkarnain Md Eusope said the vaccine would be the first to be manufactured in Malaysia at the small volume injectable high-tech plant owned by Pharmaniaga
KUALA LUMPUR (Jan 12): Pharmaniaga Bhd is partnering with China's Sinovac Life Sciences Co Ltd for the supply of 14 million doses of Covid-19 vaccine in Malaysia. Pharmaniaga expects the vaccine to be distributed to the public by the end of March this year, according to managing director Datuk Zulkarnain Md Eusope. This will cover 22% of the country’s total population.
Phamaniaga all set to manufacture Sinovac Covid-19 vaccine
A
-
Phamaniaga Bhd has the capacity to manufacture two million doses of Covid-19 vaccine developed by China’s Sinovac Life Sciences Co Ltd per month beginning March this year.
Group managing director Zulkarnain Md Eusope said the vaccine would be the first to be manufactured in Malaysia at the small volume injectable high-tech plant owned by Pharmaniaga s wholly-owned subsidiary, Pharmaniaga LifeSciences Sdn Bhd, in Puchong.
He said the group would invest RM3 million to retrofit the plant.
All Access Plan